News
CASI
2.250
+0.45%
0.010
Weekly Report: what happened at CASI last week (0408-0412)?
Weekly Report · 5d ago
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
CASI Pharmaceuticals says Juventas Cell Therapy Ltd. Is prohibited from commercializing CNCT19 by itself or through a third party. An emergency arbitrator has granted the Company injunctive relief in the dispute. The parties will cooperate to reach a temporary arrangement to commercialize the drug.
Benzinga · 04/08 21:03
*CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
Dow Jones · 04/08 21:02
*CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
Dow Jones · 04/08 21:02
CASI PHARMACEUTICALS: TO VIGOROUSLY ASSERT, ENFORCE RIGHTS IN ARBITRATION PROCEEDING AND NEGOTIATE WITH JUVENTAS IN GOOD FAITH
Reuters · 04/08 21:00
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals, Inc. Has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. The company is a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.
Barchart · 04/08 16:00
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute with Juventas Cell Therapy Ltd Prohibiting Juventas from Commercializing CNCT19
CASI Pharmaceuticals, Inc. Has a dispute with Juventas Cell Therapy Ltd. An emergency arbitrator has granted emergency injunctive relief to CASI in the dispute. The parties must cooperate to reach a temporary arrangement to provide CNCT19 to new patients, the company says.
Benzinga · 04/08 11:34
CASI PHARMACEUTICALS- CASI PHARMACEUTICALS RECEIVED EMERGENCY RELIEF IN CONNECTION WITH THE DISPUTE WITH JUVENTAS
Reuters · 04/08 11:25
CASI PHARMACEUTICALS- INTENDS TO NEGOTIATE WITH JUVENTAS IN GOOD FAITH THE TEMPORARY ARRANGEMENT FOR NEW PATIENTS’ ACCESS TO CNCT19 TREATMENT
Reuters · 04/08 11:25
Weekly Report: what happened at CASI last week (0401-0405)?
Weekly Report · 04/08 11:03
Weekly Report: what happened at CASI last week (0325-0329)?
Weekly Report · 04/01 11:01
Pre-Market Earnings Report for April 1, 2024 : SGML, DPSI, ONDS, CASI, LMFA, LGMK
NASDAQ · 03/28 20:00
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
CASI Pharmaceuticals reported earnings per share of -45 cents for the fourth quarter of 2023. The company reported revenue of $6.87 million. This was 26.95% worse than the analyst estimate for revenue. CASI reported results for the quarter.
Investorplace · 03/28 16:53
Recap: CASI Pharmaceuticals Q4 Earnings
CASI Pharmaceuticals will report its Q4 earnings on March 28. The company missed its earnings estimate by $0.45. CASi Pharmaceuticals's revenue was down $8.38 million from the same period last year. The stock dropped 3.0% after the announcement.
Benzinga · 03/28 12:20
CASI Pharmaceuticals FY2023 GAAP EPS $(2.02) Misses $(1.93) Estimate, Sales $33.88M Miss $36.42M Estimate
CASI Pharmaceuticals reported quarterly losses of $2.02 per share. The company reported quarterly sales of $33.88 million which missed the analyst consensus estimate of $36.42 million by 6.97%. The company also reported a 32.89 percent increase in losses from the same period last year.
Benzinga · 03/28 11:29
CASI Pharmaceuticals GAAP EPS of -$2.02, revenue of $33.88M
Seeking Alpha · 03/28 11:22
*CASI Pharmaceuticals 4Q Rev $6.9M >CASI
Dow Jones · 03/28 11:03
Press Release: CASI PHARMACEUTICALS ANNOUNCES -2-
CASI Pharmaceuticals, Inc. Is a biopharmaceutical company focused on developing and commercializing innovative drugs in China. The company's net loss for the year ended December 31, 2023 was $26.3 million. CASI's sales and marketing expenses increased due to the cancellation of the stringent COVID-19.
Dow Jones · 03/28 11:00
Press Release: CASI PHARMACEUTICALS ANNOUNCES -3-
CASI Pharmaceuticals, Inc. Has a total of 691,766 shares of common stock. The company's common stock has a paid-in capital of 695,785. CASI has no debt and no liabilities. The Company has a net loss for the year ended December 31, 2017 of $8.2 million. The corporation has a cash balance of $7.1 million and no debt.
Dow Jones · 03/28 11:00
Press Release: CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals, Inc. Reports business and financial results for the year ended December 31, 2023. CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA(R) and $34 million for 2023 full-year revenue. The first patient was dosed with FOLOTYN( R) in China on February 15, 2024.
Dow Jones · 03/28 11:00
More
Webull provides a variety of real-time CASI stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.